Ultragenyx Pharmaceutical Inc.

NasdaqGS:RARE Stock Report

Market Cap: US$3.4b

Ultragenyx Pharmaceutical Future Growth

Future criteria checks 5/6

Ultragenyx Pharmaceutical is forecast to grow earnings and revenue by 64.8% and 30% per annum respectively. EPS is expected to grow by 64.3% per annum. Return on equity is forecast to be -38% in 3 years.

Key information

64.8%

Earnings growth rate

64.3%

EPS growth rate

Biotechs earnings growth24.0%
Revenue growth rate30.0%
Future return on equity-38.0%
Analyst coverage

Good

Last updated09 May 2025

Recent future growth updates

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 09
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Recent updates

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 09
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being

May 08
Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being

Ultragenyx Pharmaceutical (NASDAQ:RARE) Is Carrying A Fair Bit Of Debt

Apr 07
Ultragenyx Pharmaceutical (NASDAQ:RARE) Is Carrying A Fair Bit Of Debt
author-image

FDA Progress Will Accelerate Approval Of UX111 And UX143 In 2025

Mar 21 Global expansion and gene therapy product approvals are positioned to significantly enhance revenue streams and overall earnings.

Ultragenyx Pharmaceutical: Advancing On Multiple Fronts

Jan 29

Does Ultragenyx Pharmaceutical (NASDAQ:RARE) Have A Healthy Balance Sheet?

Dec 31
Does Ultragenyx Pharmaceutical (NASDAQ:RARE) Have A Healthy Balance Sheet?

Ultragenyx: Ready For More Growth After Q3 Earnings Beat

Nov 12

Ultragenyx: Excellent Company, Lackluster Stock

Nov 06

We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

Sep 04
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective

Aug 22

There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump

Aug 03
There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump

Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being

Jun 12
Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being

Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching

Jun 06

We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

May 24
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt

Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet

Mar 09

Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?

Feb 01
Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?

There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise

Dec 28
There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise

Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?

Sep 12
Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?

Earnings and Revenue Growth Forecasts

NasdaqGS:RARE - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20271,250341755615
12/31/2026842-363-160-24819
12/31/2025649-518-216-33519
3/31/2025591-550-413-390N/A
12/31/2024560-569-434-414N/A
9/30/2024523-559-440-419N/A
6/30/2024481-585-492-469N/A
3/31/2024443-613-544-509N/A
12/31/2023434-607-522-475N/A
9/30/2023410-635-553-481N/A
6/30/2023403-721-553-459N/A
3/31/2023384-719-529-420N/A
12/31/2022363-707-527-380N/A
9/30/2022343-678-480-344N/A
6/30/2022334-506-438-309N/A
3/31/2022332-470-416-297N/A
12/31/2021351-454-412-339N/A
9/30/2021360-356-426-347N/A
6/30/2021359-351-411-349N/A
3/31/2021334-204-243-196N/A
12/31/2020271-187-176-132N/A
9/30/2020215-256-175-142N/A
6/30/2020159-301-203-168N/A
3/31/2020122-425-381-345N/A
12/31/2019104-403-370-345N/A
9/30/201984-397-344-329N/A
6/30/201970-371-320-310N/A
3/31/201959-325-304-297N/A
12/31/201851-198N/A-291N/A
9/30/201838-192N/A-317N/A
6/30/201826-183N/A-309N/A
3/31/201813-204N/A-282N/A
12/31/20173-302N/A-254N/A
9/30/20170-292N/A-220N/A
6/30/20170-277N/A-186N/A
3/31/20170-261N/A-177N/A
12/31/20160-246N/A-161N/A
9/30/20160-230N/A-154N/A
6/30/20160-204N/A-156N/A
3/31/2016N/A-177N/A-133N/A
12/31/2015N/A-146N/A-106N/A
9/30/2015N/A-107N/A-78N/A
6/30/2015N/A-84N/A-58N/A
3/31/2015N/A-68N/A-52N/A
12/31/2014N/A-65N/A-45N/A
9/30/2014N/A-67N/A-42N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RARE is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.8%).

Earnings vs Market: RARE is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RARE is expected to become profitable in the next 3 years.

Revenue vs Market: RARE's revenue (30% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: RARE's revenue (30% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: RARE is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/09 06:34
End of Day Share Price 2025/05/09 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ultragenyx Pharmaceutical Inc. is covered by 35 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Huidong WangBarclays
Tazeen AhmadBofA Global Research